Diaz Stephanie 4
4 · PALISADE BIO, INC. · Filed Apr 29, 2021
Insider Transaction Report
Form 4
Diaz Stephanie
Director
Transactions
- Award
Stock Option (Right to Buy)
2021-04-27+10,203→ 10,203 totalExercise: $41.20Exp: 2029-06-19→ Common Stock (10,203 underlying) - Award
Stock Option (Right to Buy)
2021-04-27+4,406→ 4,406 totalExercise: $26.85Exp: 2030-07-10→ Common Stock (4,406 underlying)
Footnotes (4)
- [F1]The stock option vested in four equal quarterly installments from June 30, 2019.
- [F2]Received in exchange for a stock option to acquire 375,250 shares of common stock of Leading BioSciences, Inc. ("LBS") for $1.12 per share, pursuant to the Agreement and Plan of Merger, dated December 16, 2020, among Seneca Biopharma Inc., Townsgate Acquisition Sub 1, Inc. and LBS (the "Merger"). Per the terms of the Merger, each share of LBS's common stock was converted into the right to receive 0.02719 shares of Seneca's common stock. In the Merger, the name of the Issuer was changed from Seneca Biopharma, Inc. to Palisade Bio, Inc.
- [F3]The stock option vests according to the following schedule: 25% of the shares underlying the option vests on grant date and the remaining 75% vests in three equal quarterly installments thereafter beginning September 30, 2020.
- [F4]Received in the Merger in exchange for a stock option to acquire 162,069 shares of LBS common stock for $0.73 per share.